歐菲光(002456.SZ):公司光學鏡頭業務進展順利,高端鏡頭加速滲透,產品結構持續完善
格隆匯5月29日丨歐菲光(002456.SZ)在互動平臺表示,公司憑藉深厚的技術積累,產品持續創新升級,通過產業鏈的平臺化整合,在光學影像領域發展迅速,積累了優質的客戶資源,躋身於行業前列。公司光學鏡頭業務進展順利,高端鏡頭加速滲透,產品結構持續完善。團隊歷經多年技術沉澱,突破高端鏡頭技術壁壘。目前 7P 光學鏡頭、潛望長焦鏡頭、雙羣內對焦鏡頭、可變光圈鏡頭等高端產品均已成功量產,並進入國內主流手機廠商旗艦項目供應鏈。公司保持技術創新, 8P 高像素主攝、三羣連續變焦、玻塑混合等前沿鏡頭項目已研發成功。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.